- Home
- DQ vs GYRE Comparison
DQ vs GYRE Comparison
Compare DQ & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DQ
- GYRE
- Stock Information
- Founded
- DQ 2006
- GYRE 2002
- Country
- DQ China
- GYRE United States
- Employees
- DQ N/A
- GYRE N/A
- Industry
- DQ Semiconductors
- GYRE Biotechnology: Pharmaceutical Preparations
- Sector
- DQ Technology
- GYRE Health Care
- Exchange
- DQ Nasdaq
- GYRE Nasdaq
- Market Cap
- DQ 1.4B
- GYRE 1.3B
- IPO Year
- DQ 2010
- GYRE N/A
- Fundamental
- Price
- DQ $19.22
- GYRE $13.12
- Analyst Decision
- DQ Hold
- GYRE
- Analyst Count
- DQ 5
- GYRE 0
- Target Price
- DQ $20.31
- GYRE N/A
- AVG Volume (30 Days)
- DQ 2.5M
- GYRE 53.3K
- Earning Date
- DQ 10-30-2024
- GYRE 11-13-2024
- Dividend Yield
- DQ N/A
- GYRE N/A
- EPS Growth
- DQ N/A
- GYRE N/A
- EPS
- DQ N/A
- GYRE N/A
- Revenue
- DQ $1,310,019,000.00
- GYRE $105,033,000.00
- Revenue This Year
- DQ N/A
- GYRE $25.32
- Revenue Next Year
- DQ $47.79
- GYRE $12.95
- P/E Ratio
- DQ N/A
- GYRE N/A
- Revenue Growth
- DQ N/A
- GYRE N/A
- 52 Week Low
- DQ $13.62
- GYRE $8.26
- 52 Week High
- DQ $30.85
- GYRE $30.40
- Technical
- Relative Strength Index (RSI)
- DQ 42.58
- GYRE 41.11
- Support Level
- DQ $20.50
- GYRE $13.07
- Resistance Level
- DQ $22.31
- GYRE $19.00
- Average True Range (ATR)
- DQ 1.72
- GYRE 1.16
- MACD
- DQ -0.54
- GYRE -0.21
- Stochastic Oscillator
- DQ 0.29
- GYRE 7.39
About DQ DAQO New Energy Corp.
Daqo New Energy Corp is a polysilicon manufacturer based in China. The company manufactures and sells high-purity polysilicon to manufacturers who use it to make ingots, cells, and modules for solar power solutions. The polysilicon is packaged to meet crucible stacking, pulling, and solidification needs. All of the company's revenues come from the People's Republic of China.
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230.